Because abnormal protein expression is associated with many human diseases, biomarker discovery is fundamental to diagnostic innovation. Clinical and research labs need a new state-of-the-art analytical technology for protein detection and quantitation at the whole proteome level. Current biochemical and immuno-assays have many limitations and are expensive to perform in high volumes. Moreover, the high volume of biomarkers identified in the discovery phase means that only a small fraction are able to be validated and subsequently translated into clinical tests.
Description
MATS Proteomics Technology was developed to accurately measure the absolute amounts of thousands of proteins in a complex biological sample. This novel hybrid technology combines mass spectrometry techniques and machine learning to perform absolute protein quantitation in plasma, urine, or tissue samples at the proteome level. Our MATS Proteomics Technology is a game changer in the field of clinical diagnostics for personalized patient care and will revolutionize a medical testing market in which more than one billion tests are performed per year just in the United States.
Applications
· Measure the differential expression levels of thousands of proteins in human plasma, urine, and other biofluids, tissue, or FFPE samples
· Identify and validate diagnostic biomarkers and drug targets
· Serve as a new generation clinical test that iterative enhances the sensitivity and specificity of the testing algorithms as more and more samples are analyzed
· Treating cancer, depression, and kidney diseases
· Revolutionizing personalized patient care
Advantages
· Enables a new generation of clinical tests with built-in biomarker discovery research component
· Allows instant and iterative validation of biomarker using machine learning-based prediction models.
IP Status
Copyright
